mRNA-1283-P301 PART 2 Covid-19

A randomized, observer-blind, active-controlled Phase 3 study to investigate the safety, immunogenicity, and relative vaccine efficacy of mRNA-1283 compared with mRNA-1273 in participants aged ≥12 years for the prevention of COVID-19. Register Today!


A phase 3 randomized, double-blind, 52-week placebocontrolled multi-center study with a double-blind 52-week extension period with randomized dose up/dose down titration investigating the efficacy, safety, and tolerability of Ritlecitinib in adult participants with nonsegmental vitiligo. Register Today!

Vaccine (RSV) – 222090 (extension to 212494)

A phase 3b, randomized, open label, multi-country, multi-center, extension and crossover vaccination study to evaluate the immunogenicity and safety of different revaccination schedules and persistence of a single dose of the RSVPreF3 OA vaccine in adults aged 60 years and above who participated in the RSV OA=ADJ-006 study. Register Today!

Atopic Dermatitis – M16-047 (extension to M18-891)

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis For more information, please click here. Register Today!

Atopic Dermatitis – C4531002

Atopic dermatitis or eczema as it is commonly known, is a condition that makes your skin red and itchy. The disease is common in children but can also occur at any age. Eczema is a chronic condition that tends to flare up periodically. There is currently no cure for eczema, but treatments and self-care measures…

Alopecia Areata – M23-716

A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata Register Today!